Tuesday, December 15, 2009
Improving Outcomes in Breast Cancer: Update from the 32nd Annual San Antonio Breast Cancer Symposium
Statement of Need
In 2008, breast cancer accounted for approximately 26% of all new cancer diagnoses and 15% of cancer-related deaths for women in the US. An estimated 182,460 new cases of invasive breast cancer will be diagnosed and 40,480 women will die from this disease. Following the two-decade rise that began in the 1980s, the incidence rate for breast cancer decreased by 3.5% a year from 2001-2004. It has been postulated that this may be related to the reduction in the use of hormone replacement therapy and the adoption of mammography screening. Fortunately, the death rate for women with breast cancer has also declined by about 20% from 1991 (32.69 deaths per 100,000) to 2003 (25.19 deaths per 100,000). It is estimated that 15% of the decline in breast cancer mortality was due to screening mammography and 19% was related to adjuvant treatments. Significant improvements have occurred in the management of women with breast cancer although many questions remain. As clinicians encounter these patients in practice and need to make informed decisions about controversial treatment topics, discussion and debate of these issues are necessary to improve the long-term outcomes of these patients.
Target Audience
This educational activity is intended for oncologists, hematologist-oncologists, surgical oncologists, radiation oncologists, and allied oncology healthcare providers caring for patients with breast cancer.
Learning Objectives
Upon completion of this educational activity, participants should be better able to:
- Recognize biologic pathways of significance in breast cancer pathogenesis and resistance and their implications on treatment selection and response
- Discuss updated efficacy and toxicity data for adjuvant therapy options used in the early breast cancer setting
- Describe the strengths and weaknesses of significant clinical trials of agents designed to improve response and survival rates in the metastatic breast cancer setting
- Describe the potential role of novel treatment approaches in the management of breast cancer
- Compare treatment options available for the treatment of patients with breast cancer with respect to efficacy and toxicity parameters
|
Accreditation Information
PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
| PHARMACIST CONTINUING EDUCATION |
|
Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
Educational Concepts Group, LLC designates this
continuing education activity for 1.0 contact hour
(0.10 CEU) (UAN 0199-0000-09-080-H01-P).
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity. Participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the evaluation. For ACPE credit, participants must complete a post-test for all categories.
CME/CE CREDIT
Physicians and pharmacists who complete the evaluation may view and print their credit letter or statement of credit via the ECG website, www.educationalconcepts.net.
Click here to access archive
|
